Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market
This article was originally published in PharmAsia News
Executive Summary
BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound
You may also be interested in...
As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In China
The center in Beijing will become the third in a triumvirate of global research sites that Bayer oversees, and its Chinese scientists will be closely linked with their colleagues in Germany and the U.S.
As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In China
The center in Beijing will become the third in a triumvirate of global research sites that Bayer oversees, and its Chinese scientists will be closely linked with their colleagues in Germany and the U.S.
As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In Rising China
BEIJING - German pharmaceutical powerhouse Bayer Schering is engineering an alliance with Chinese scientists to create a global research and development center in Beijing, according to senior Bayer executives